View in EDS

Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial.

Saved in:
Bibliographic Details
Title: Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial.
Authors: Sellier-Leclerc AL; Hôpital Femme Mère Enfant en Centre d'Investigation Clinique INSERM, Hospices Civils de Lyon, ERKnet, Bron, France., Magen D; Pediatric Nephrology Institute, Rambam Health Care Campus, Haifa, Israel., Shasha-Lavsky H; Pediatric Nephrology Unit, Galilee Medical Center, Nahariya, Israel., Simkova E; Nephrology - Medical Affairs, Al Jalila Children's Specialty Hospital, Dubai, United Arab Emirates., Devresse A; Division of Nephrology, Cliniques universitaires Saint-Luc, Brussels, Belgium., Guebre-Egziabher F; Nephrology and Renal Function Unit, Edouard Herriot Hospital, Hospices Civils de Lyon, INSERM 1060, Lyon, France., Michael M; Division of Pediatric Nephrology, Department of Pedatrics, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas., Lieske JC; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota., Frishberg Y; Division of Pediatric Nephrology, Shaare Zedek Medical Center, Jerusalem, Israel; Faculty of Medicine, Hebrew University, Jerusalem, Israel., Bakkaloglu SA; Department of Pediatric Nephrology, Faculty of Medicine, Gazi University, Ankara, Turkey., Mourani C; Pediatrics, Hôtel Dieu de France Hospital (HDF), Beirut, Lebanon., Saqan R; Pharmaceutical Research Center - Jordan University of Science and Technology, Irbid, Jordan., Singer R; Renal Service, Canberra Health Services, Garran, Australia., Guzzo I; Nephrology, Dialysis, and Transplant Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy., Makarova N; Alnylam Pharmaceuticals, Cambridge, Massachusetts., Willey R; Alnylam Pharmaceuticals, Cambridge, Massachusetts., Kaspar C; Alnylam Pharmaceuticals, Cambridge, Massachusetts., Gansner JM; Alnylam Pharmaceuticals, Cambridge, Massachusetts., Groothoff JW; Department of Pediatric Nephrology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands. Electronic address: j.w.groothoff@amsterdamumc.nl.
Source: American journal of kidney diseases : the official journal of the National Kidney Foundation [Am J Kidney Dis] 2025 Aug; Vol. 86 (2), pp. 285-288. Date of Electronic Publication: 2025 Mar 13.
Publication Type: Letter
Journal Info: Publisher: W.B. Saunders Country of Publication: United States NLM ID: 8110075 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1523-6838 (Electronic) Linking ISSN: 02726386 NLM ISO Abbreviation: Am J Kidney Dis Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40086686
AccessLevel: 2
PubType: Editorial & Opinion
PubTypeId: editorialOpinion
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Sellier-Leclerc+AL%22">Sellier-Leclerc AL</searchLink>; Hôpital Femme Mère Enfant en Centre d'Investigation Clinique INSERM, Hospices Civils de Lyon, ERKnet, Bron, France.<br /><searchLink fieldCode="AU" term="%22Magen+D%22">Magen D</searchLink>; Pediatric Nephrology Institute, Rambam Health Care Campus, Haifa, Israel.<br /><searchLink fieldCode="AU" term="%22Shasha-Lavsky+H%22">Shasha-Lavsky H</searchLink>; Pediatric Nephrology Unit, Galilee Medical Center, Nahariya, Israel.<br /><searchLink fieldCode="AU" term="%22Simkova+E%22">Simkova E</searchLink>; Nephrology - Medical Affairs, Al Jalila Children's Specialty Hospital, Dubai, United Arab Emirates.<br /><searchLink fieldCode="AU" term="%22Devresse+A%22">Devresse A</searchLink>; Division of Nephrology, Cliniques universitaires Saint-Luc, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Guebre-Egziabher+F%22">Guebre-Egziabher F</searchLink>; Nephrology and Renal Function Unit, Edouard Herriot Hospital, Hospices Civils de Lyon, INSERM 1060, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Michael+M%22">Michael M</searchLink>; Division of Pediatric Nephrology, Department of Pedatrics, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Lieske+JC%22">Lieske JC</searchLink>; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.<br /><searchLink fieldCode="AU" term="%22Frishberg+Y%22">Frishberg Y</searchLink>; Division of Pediatric Nephrology, Shaare Zedek Medical Center, Jerusalem, Israel; Faculty of Medicine, Hebrew University, Jerusalem, Israel.<br /><searchLink fieldCode="AU" term="%22Bakkaloglu+SA%22">Bakkaloglu SA</searchLink>; Department of Pediatric Nephrology, Faculty of Medicine, Gazi University, Ankara, Turkey.<br /><searchLink fieldCode="AU" term="%22Mourani+C%22">Mourani C</searchLink>; Pediatrics, Hôtel Dieu de France Hospital (HDF), Beirut, Lebanon.<br /><searchLink fieldCode="AU" term="%22Saqan+R%22">Saqan R</searchLink>; Pharmaceutical Research Center - Jordan University of Science and Technology, Irbid, Jordan.<br /><searchLink fieldCode="AU" term="%22Singer+R%22">Singer R</searchLink>; Renal Service, Canberra Health Services, Garran, Australia.<br /><searchLink fieldCode="AU" term="%22Guzzo+I%22">Guzzo I</searchLink>; Nephrology, Dialysis, and Transplant Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.<br /><searchLink fieldCode="AU" term="%22Makarova+N%22">Makarova N</searchLink>; Alnylam Pharmaceuticals, Cambridge, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Willey+R%22">Willey R</searchLink>; Alnylam Pharmaceuticals, Cambridge, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Kaspar+C%22">Kaspar C</searchLink>; Alnylam Pharmaceuticals, Cambridge, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Gansner+JM%22">Gansner JM</searchLink>; Alnylam Pharmaceuticals, Cambridge, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Groothoff+JW%22">Groothoff JW</searchLink>; Department of Pediatric Nephrology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands. Electronic address: j.w.groothoff@amsterdamumc.nl.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228110075%22">American journal of kidney diseases : the official journal of the National Kidney Foundation</searchLink> [Am J Kidney Dis] 2025 Aug; Vol. 86 (2), pp. 285-288. <i>Date of Electronic Publication: </i>2025 Mar 13.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Letter
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22W%2EB%2E+Saunders%22">W.B. Saunders </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8110075 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1523-6838 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2202726386%22">02726386 </searchLink><i>NLM ISO Abbreviation: </i>Am J Kidney Dis <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40086686
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1053/j.ajkd.2025.01.016
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 285
    Titles:
      – TitleFull: Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sellier-Leclerc AL
      – PersonEntity:
          Name:
            NameFull: Magen D
      – PersonEntity:
          Name:
            NameFull: Shasha-Lavsky H
      – PersonEntity:
          Name:
            NameFull: Simkova E
      – PersonEntity:
          Name:
            NameFull: Devresse A
      – PersonEntity:
          Name:
            NameFull: Guebre-Egziabher F
      – PersonEntity:
          Name:
            NameFull: Michael M
      – PersonEntity:
          Name:
            NameFull: Lieske JC
      – PersonEntity:
          Name:
            NameFull: Frishberg Y
      – PersonEntity:
          Name:
            NameFull: Bakkaloglu SA
      – PersonEntity:
          Name:
            NameFull: Mourani C
      – PersonEntity:
          Name:
            NameFull: Saqan R
      – PersonEntity:
          Name:
            NameFull: Singer R
      – PersonEntity:
          Name:
            NameFull: Guzzo I
      – PersonEntity:
          Name:
            NameFull: Makarova N
      – PersonEntity:
          Name:
            NameFull: Willey R
      – PersonEntity:
          Name:
            NameFull: Kaspar C
      – PersonEntity:
          Name:
            NameFull: Gansner JM
      – PersonEntity:
          Name:
            NameFull: Groothoff JW
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2025 Aug
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1523-6838
          Numbering:
            – Type: volume
              Value: 86
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: American journal of kidney diseases : the official journal of the National Kidney Foundation
              Type: main
ResultId 1